id: lack_effective_therapeutic_agents_to_chronic_pancreatitis_disease_progression
name: Lack of Effective Therapeutic Agents for Chronic Pancreatitis â†’ Chronic Pancreatitis
  Disease Progression
from_node:
  node_id: lack_effective_therapeutic_agents
  node_name: Lack of Effective Therapeutic Agents for Chronic Pancreatitis
to_node:
  node_id: chronic_pancreatitis_disease_progression
  node_name: Chronic Pancreatitis Disease Progression
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Absence of disease-modifying therapeutic agents prevents intervention on
  underlying pathophysiological mechanisms of CP'
- 'Step 2: Without effective drugs to halt inflammation, fibrosis, and cellular damage,
  disease continues to advance'
- 'Step 3: Progressive pancreatic damage leads to worsening exocrine and endocrine
  dysfunction'
- 'Step 4: Systematic gap in drug development pipeline creates structural barrier
  to preventing disease progression across patient populations'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'C. Forsmark et al. 2018. "Accelerating the Drug Delivery Pipeline
    for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development
    and Trials in Chronic Pancreatitis at the National Institute of Diabetes and Digestive
    and Kidney Diseases Workshop.." *Pancreas*. https://doi.org/10.1097/MPA.0000000000001174'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.158668'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/lack_effective_therapeutic_agents_to_chronic_pancreatitis_disease_progression.yaml
_category: healthcare_access
